Lead Sheet

Real-time Expert BD Intelligence

CROs, CMOs and CDMOs worldwide depend on the PharmSource Lead Sheet for fresh leads, up-to-date contact information and reliable market intelligence. Quickly scout well-targeted new business opportunities. Learn more

Strategic Advantage

Proprietary Global Sourcing Intelligence in an Instant

Decision-makers at CMOs, CDMOs and Bio/Pharma companies rely on Strategic Advantage, to understand industry trends and company capabilities. Quickly get hard-to-find information and benefit from PharmSource’s trademark quantitative approach to analysis. Learn more


Quality Systems, Data Integrity among Most Frequent Problems Cited by MHRA

Pharmaceutical manufacturers around the world, including CMOs, subject to inspection by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) can expect to see a more intense focus on quality systems and data integrity.

Problems related to quality systems are the most prevalent observations during…

Our Thinking

Outlook for the CMO Industry

The outlook for the contract manufacturing industry is being shaped by several significant trends. The well-financed pipeline makes the near term outlook favorable, but much depends on the number of new approvals for small and mid-size companies. Injectables CMOs should…

Market Intelligence

Demand and Supply for Contract Manufacturing of Conventional Injectable Drugs Through 2019

This extensive study estimates the demand for contract injectable manufacturing through 2019 and analyzes the supply and demand relationships for these services. Accompanied by a report on the cytotoxic injectable drug outlook, this expert report covers…

Trend Reports

Opportunity Knocks:
In-Licensed Drug Products Can Signal Outsourcing Opportunity

Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between products originally discovered in-house and those in-licensed from external partners. During this period…